The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

An mRNA success is something of a vindication for Trump (and the Biden years), but an embarrassment for RFK Jr.

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage ...

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Simon Baker, Rothschild & Co Redburn global biopharma research co-head, joins 'Squawk on the Street' to discuss Moderna and ...

Courtney Breen, Bernstein, joins 'Closing Bell Overtime' to talk Merck and Moderna stocks rallying on news of cancer drug ...